rss
Br J Ophthalmol 2005;89:647 doi:10.1136/bjo.2005.bjjun05at%20a%20glance
  • BJO at a glance

BJO at a glance

  1. Creig Hoyt, Editor

      SIROLIMUS TREATMENT FOR UVEITIS

      Sirolimus was originally developed as an antibiotic. Its potential as an immunomodulatory agent has been established for the prevention of allograft rejection following solid organ transplantation. Shanmuganathan and co-workers report the use of sirolimus in eight patients with severe non-infectious uveitis. It appeared to be an effective and potent immunosuppressant treatment in these patients. See p 666

      DECREASED ANTIOXIDANT STATUS IN DIABETIC RETINOPATHY

      The formation and accumulation of advanced glycation end products (AGE) is known to progress during normal aging and is extremely accelerated in diabetes mellitus. Yokoi and co-workers report that in the vitreous of patients with diabetic retinopathy there are increased levels of advanced glycation end products. The vitreous levels of AGE and VEGF (vascular growth factor) …

      [Full text of this article]

      This Article

      1. Extract
      2. Full text
      3. PDF

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.